Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Second Consecutive Year Of Growth In NME Approvals In The Cards For FDA

Executive Summary

It looks to be a good bet that 2009 will mark a second year of growth in new drug approvals: FDA entered the second half of the year with a robust first-half NME approval tally and a well-stocked pipeline of novel agents with user fee goal dates in the remaining months of the year

You may also be interested in...



The REMS Ramp Up: FDA Using New Safety Tools More Frequently In Year Two

FDA is using its new Risk Evaluation and Mitigation Strategy authorities much more frequently in the second year since the law took effect

The REMS Ramp Up: FDA Using New Safety Tools More Frequently In Year Two

FDA is using its new Risk Evaluation and Mitigation Strategy authorities much more frequently in the second year since the law took effect

Chart: Biologicals Approved In 2009

Biologicals Approved In 2009

Related Content

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel